1. Home
  2. CYTK vs GHC Comparison

CYTK vs GHC Comparison

Compare CYTK & GHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • GHC
  • Stock Information
  • Founded
  • CYTK 1997
  • GHC 1877
  • Country
  • CYTK United States
  • GHC United States
  • Employees
  • CYTK N/A
  • GHC N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • GHC Other Consumer Services
  • Sector
  • CYTK Health Care
  • GHC Real Estate
  • Exchange
  • CYTK Nasdaq
  • GHC Nasdaq
  • Market Cap
  • CYTK 4.6B
  • GHC 5.1B
  • IPO Year
  • CYTK 2004
  • GHC N/A
  • Fundamental
  • Price
  • CYTK $59.89
  • GHC $1,098.43
  • Analyst Decision
  • CYTK Buy
  • GHC
  • Analyst Count
  • CYTK 16
  • GHC 0
  • Target Price
  • CYTK $76.73
  • GHC N/A
  • AVG Volume (30 Days)
  • CYTK 2.5M
  • GHC 45.3K
  • Earning Date
  • CYTK 11-05-2025
  • GHC 10-29-2025
  • Dividend Yield
  • CYTK N/A
  • GHC 0.66%
  • EPS Growth
  • CYTK N/A
  • GHC 426.70
  • EPS
  • CYTK N/A
  • GHC 155.13
  • Revenue
  • CYTK $85,738,000.00
  • GHC $4,834,649,000.00
  • Revenue This Year
  • CYTK $363.61
  • GHC $0.54
  • Revenue Next Year
  • CYTK $64.08
  • GHC $6.39
  • P/E Ratio
  • CYTK N/A
  • GHC $7.06
  • Revenue Growth
  • CYTK 2635.74
  • GHC 4.73
  • 52 Week Low
  • CYTK $29.31
  • GHC $770.06
  • 52 Week High
  • CYTK $61.19
  • GHC $1,200.00
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 75.04
  • GHC 43.26
  • Support Level
  • CYTK $47.22
  • GHC $1,140.21
  • Resistance Level
  • CYTK $50.78
  • GHC $1,182.94
  • Average True Range (ATR)
  • CYTK 2.30
  • GHC 24.31
  • MACD
  • CYTK 0.66
  • GHC -9.37
  • Stochastic Oscillator
  • CYTK 90.55
  • GHC 0.00

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About GHC Graham Holdings Company

Graham Holdings Co. is a diversified education and media company made up of subsidiaries. Firm operations include educational services; television broadcasting; online, print, and local news; home health and hospice care; and manufacturing. The Company segments into the following seven reportable segments: Kaplan International, Higher Education, Supplemental Education, Television Broadcasting, Manufacturing, Healthcare, and Automotive. The majority of revenue comes from the Kaplan International segment, which includes higher education, test preparation, language instruction, and professional training. A large portion of company revenue also comes from the television broadcasting segment through advertising.

Share on Social Networks: